Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Free Report) Director Arvind Kush bought 145,000 shares of the stock in a transaction dated Monday, October 21st. The stock was purchased at an average price of $1.37 per share, with a total value of $198,650.00. Following the purchase, the director now owns 145,000 shares in the company, valued at $198,650. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Inhibikase Therapeutics Trading Up 15.2 %
Shares of IKT opened at $2.43 on Thursday. The firm has a market cap of $17.53 million, a PE ratio of -0.73 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a 1-year low of $0.80 and a 1-year high of $3.82. The firm has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.51.
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). As a group, research analysts forecast that Inhibikase Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.
Institutional Investors Weigh In On Inhibikase Therapeutics
Analyst Ratings Changes
Separately, HC Wainwright lowered their price objective on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 14th.
View Our Latest Stock Analysis on Inhibikase Therapeutics
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
Featured Stories
- Five stocks we like better than Inhibikase Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Read Stock Charts for Beginners
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.